General Information of Drug (ID: DMNAJGK)

Drug Name
MK-0963 Drug Info
Synonyms L-654066; MK-963; (5alpha)-23-Methyl-4-aza-21-norchol-1-ene-3,20-dione; 23-Methyl-21-nor-4-aza-5alpha-chol-1-ene-3,20-dione
Indication
Disease Entry ICD 11 Status REF
Prostate disease GA91 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
6918127
CAS Number
CAS 103497-68-3
TTD Drug ID
DMNAJGK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Finasteride DMWV3TZ Baldness, male pattern Approved [3]
Dutasteride DMQ4TJK Benign prostatic hyperplasia GA90 Approved [3]
Polyestradiol Phosphate DM0PMGJ Prostate cancer 2C82.0 Approved [4]
Azelaic Acid DMHVL0J Acne vulgaris ED80 Approved [5]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [6]
Epristeride DM35T1O Hirsutism ED72 Phase 3 [7]
FK-143 DMEL15U Prostate disease GA91 Phase 2 [8]
Turosteride DMW7PFS Prostate disease GA91 Phase 2 [9]
IZONSTERIDE DM3KXMG Hirsutism ED72 Phase 1/2 [10]
ONO-3805 DM1RKWV Prostate disease GA91 Discontinued in Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) TT2A0DR S5A1_HUMAN; S5A2_HUMAN; PORED_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003374)
2 Pharmacodynamics of MK-0963, a new 5 alpha-reductase inhibitor: effects on serum androgen concentrations. Clin Pharmacol Ther. 1994 Jan;55(1):50-4.
3 The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.
6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7 Discovery of a novel hybrid from finasteride and epristeride as 5alpha-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8.
8 FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):357-63.
9 Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol. 1993 Nov;46(5):549-55.
10 Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible... Urology. 2004 Jan;63(1):114-9.
11 Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-redu... J Androl. 1994 Nov-Dec;15(6):521-7.